NOX-E36 - A Phase I, Double-Blind, Placebo Controlled, Single Intravenous and Subcutaneous Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects

Trial Profile

NOX-E36 - A Phase I, Double-Blind, Placebo Controlled, Single Intravenous and Subcutaneous Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 06 May 2014

At a glance

  • Drugs Emapticap pegol (Primary) ; Emapticap pegol (Primary)
  • Indications Diabetic complications; Diabetic nephropathies; Lupus nephritis
  • Focus Adverse reactions
  • Sponsors NOXXON Pharma AG
  • Most Recent Events

    • 10 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Oct 2009 New source identified and integrated (ClinicalTrials.gov record NCT00976729).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top